At the news
? BULLISHIMPACT 6/10 6-K filed Aug 3, 2026 at 06:24 ET
Dr. Reddy's announced U.S. FDA approval of its rituximab biosimilar (biosimilar to Rituxan) on the goal date, strengthening its global biosimilars portfolio. Fresenius Kabi will exclusively commercialize the product in the U.S. market, expanding Dr. Reddy's footprint in the world's largest pharmaceutical market. No financial terms were disclosed.
- U.S. FDA approved Dr. Reddy's rituximab biosimilar on the agency's goal date, following a successful pre-license inspection at its biologics facility in Bachupally, Hyderabad.
- Fresenius Kabi holds exclusive rights to commercialize the product in the United States.
- The rituximab biosimilar is already commercialized in India, the European Union, the UK, and more than 25 emerging markets, with additional approvals in Switzerland and Canada.
- The approval is supported by analytical, non-clinical and clinical evidence demonstrating high similarity to the reference product with no clinically meaningful differences in safety, purity, or potency.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access